Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
About this episode
The episode discusses the advancements in DNA repair therapies and their implications for cancer treatment.
BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE)…
More episodes of The BioMedWire Podcast
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis [Video Edition]
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology [Video Edition]
Explore listener stats, chart rankings, contacts and more on the The BioMedWire Podcast podcast page.